Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study
Kim Papp(University of Toronto), Woori Ko(Celltrion (South Korea)), Yunju Bae(Celltrion (South Korea)), Janusz Jaworski(NZOZ Centrum Alergologii), Stefan Daniluk(Medical University of Białystok), Bartłomiej Kwiek(Uczelnia Łazarskiego), Mark Lebwohl(Mount Sinai Hospital), Yuriy Andrashko(Uzhhorod National University), Hyunseung Lee(Chonnam National University Hospital), Adam Reich(Rzeszów University of Technology), Tina Pyo(Celltrion (South Korea)), Jacek C. Szepietowski(Wroclaw Medical University), DaBee Jeon(Celltrion (South Korea)), Katarzyna Bartnicka-Maslowska(Centrum Medyczne iMed24), Jinsun Jung(Celltrion (South Korea)), Diamant Thaçi(University of Lübeck), Joanna Narbutt(ENT and Allergy), Wojciech Baran(Wroclaw Medical University), Joanna Kolinek(Medical University of Białystok), Nataliya Reznichenko, SungHyun Kim(Celltrion (South Korea)), Anna Dudek, Jakub Trefler(Fundacion Instituto de Reumatologia Fernando Chalem)
Cited by 30
Related Papers
The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries
|Journal of Investigative Dermatology|2014|954
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
|Journal of the American Academy of Dermatology|2019|917
Psoriasis
|Nature Reviews Disease Primers|2016|893
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892
Clinical Classification of Itch: a Position Paper of the International Forum for the Study of Itch
|Acta Dermato Venereologica|2007|748